An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells.
Moriguchi
Hisashi
H
Chung
Raymond T
RT
Sato
Chifumi
C
D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D057026:Induced Pluripotent Stem Cells; D016898:Interferon-alpha / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use*; D012093:Replicon; D014212:Tretinoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016898:Interferon-alpha; D011804:Quinolines; D014212:Tretinoin; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid; C108475:pitavastatin